These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Autoinflammatory diseases: update on classification diagnosis and management. Pathak S; McDermott MF; Savic S J Clin Pathol; 2017 Jan; 70(1):1-8. PubMed ID: 27646526 [TBL] [Abstract][Full Text] [Related]
43. Type 2 diabetes mellitus: a metabolic autoinflammatory disease. Mandrup-Poulsen T Dermatol Clin; 2013 Jul; 31(3):495-506. PubMed ID: 23827251 [TBL] [Abstract][Full Text] [Related]
44. Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. Cantarini L; Lopalco G; Cattalini M; Vitale A; Galeazzi M; Rigante D Isr Med Assoc J; 2015 Feb; 17(2):93-7. PubMed ID: 26223084 [TBL] [Abstract][Full Text] [Related]
45. No shortcuts: new findings reinforce why nuance is the rule in genetic autoinflammatory syndromes. Tsoukas P; Canna SW Curr Opin Rheumatol; 2017 Sep; 29(5):506-515. PubMed ID: 28604422 [TBL] [Abstract][Full Text] [Related]
46. Role of biological agents in immune-mediated inflammatory diseases. Efthimiou P; Markenson JA South Med J; 2005 Feb; 98(2):192-204. PubMed ID: 15759950 [TBL] [Abstract][Full Text] [Related]
54. Working the endless puzzle of hereditary autoinflammatory disorders. Caso F; Cantarini L; Lucherini OM; Sfriso P; Fioretti M; Costa L; Vitale A; Atteno M; Galeazzi M; Muscari I; Magnotti F; Frediani B; Punzi L; Rigante D Mod Rheumatol; 2014 May; 24(3):381-9. PubMed ID: 24251993 [TBL] [Abstract][Full Text] [Related]
55. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases. Brennan FR; Cauvin A; Tibbitts J; Wolfreys A Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266 [TBL] [Abstract][Full Text] [Related]
56. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Cope AP; Feldmann M Curr Opin Immunol; 2004 Dec; 16(6):780-6. PubMed ID: 15511673 [TBL] [Abstract][Full Text] [Related]
57. Potential target of infliximab in autoimmune and inflammatory diseases. Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744 [TBL] [Abstract][Full Text] [Related]
58. [The immunomodulatory and anti-inflammatory properties of different antimicrobial agents]. Guz K; Bugla-Płoskońska G Postepy Hig Med Dosw (Online); 2007 Dec; 61():828-37. PubMed ID: 18097341 [TBL] [Abstract][Full Text] [Related]
59. XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator. van Eden W Curr Opin Investig Drugs; 2008 May; 9(5):523-33. PubMed ID: 18465663 [TBL] [Abstract][Full Text] [Related]
60. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Cantarini L; Lucherini OM; Muscari I; Frediani B; Galeazzi M; Brizi MG; Simonini G; Cimaz R Autoimmun Rev; 2012 Nov; 12(1):38-43. PubMed ID: 22884554 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]